Less is more in Corona Virus Disease 2019

both the World Health Organization guidance for the clinical management of COVID‐19 and the National Institutes of Health COVID‐19 treatment guidelines. However, the effect of glucocorticoid on patients with COVID‐19 is controversial. According to a study,[5] dexamethasone group VS standard care group was no significant difference in mortality, intensive care unit‐free days, or mechanical ventilation duration. Hence, glucocorticoid is not to use regularly. Finally, according to the above review, immunotherapy or targeted therapy is not recommended for now. We need more clinical trials for immunotherapy in COVID‐19 to guide us to personalized use. Contrary, what we think needs to be done: Proper nutritional support is another important therapy for COVID‐19, enteral nutrition, the earlier the better; then, anticoagulant therapy is necessary to prevent thrombosis. There are lots of studies that reported that thromboprophylaxis was associated with a lower risk of death and a lower cumulative incidence of thromboembolic events, especially with high doses.[6] In addition, the fever, cough, and other symptoms of the patient should be treated by symptomatic treatment. For oxygen, perform in the prone position and tidal volume for ventilation (<10 ml/kg). Last but not least, organ support such as a ventilator, continuous renal replacement therapy, and extracorporeal membrane oxygenation are in clinical trials,[1] the results are being expected.